**Core Concept**
The management of acute coronary syndromes (ACS) involves the administration of antiplatelet agents to prevent thrombus formation. Aspirin is a cornerstone in the treatment of ACS due to its antiplatelet and anti-inflammatory effects.

**Why the Correct Answer is Right**
Aspirin acts by inhibiting the enzyme cyclooxygenase (COX), specifically COX-1, which is responsible for the production of thromboxane A2 (TXA2) in platelets. TXA2 promotes platelet aggregation and vasoconstriction, leading to thrombus formation. By inhibiting COX-1, aspirin reduces the production of TXA2, thereby preventing platelet aggregation and thrombus formation. This is particularly important in the setting of ACS, where platelet activation and aggregation play a critical role in the development of occlusive thrombi.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because it does not accurately describe the mechanism of action of aspirin in the context of ACS.
**Option B:** This option is incorrect because it implies that aspirin has a direct effect on the renin-angiotensin-aldosterone system (RAAS), which is not its primary mechanism of action in the treatment of ACS.
**Option C:** This option is incorrect because it suggests that aspirin has a direct effect on the sympathetic nervous system, which is not its primary mechanism of action in the treatment of ACS.

**Clinical Pearl / High-Yield Fact**
Aspirin is a high-dose antiplatelet agent that should be administered as soon as possible in the setting of ACS, ideally within 24-48 hours of symptom onset. The recommended dose is typically 162-325 mg orally, followed by a daily maintenance dose of 81-100 mg.

**Correct Answer:** A. Aspirin inhibits COX-1, reducing thromboxane A2 production and preventing platelet aggregation.